| 10.92 -0.11 (-1%) | 06-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.12 | 1-year : | 17.26 |
| Resists | First : | 12.08 | Second : | 14.78 |
| Pivot price | 11.49  |
|||
| Supports | First : | 7.73 | Second : | 6.43 |
| MAs | MA(5) : | 11.05  |
MA(20) : | 11.11 |
| MA(100) : | 11.27 |
MA(250) : | 17.18 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 47 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 29.73 | Low : | 6.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RAPP ] has closed above bottom band by 39.1%. Bollinger Bands are 20.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.31 - 11.36 | 11.36 - 11.41 |
| Low: | 10.44 - 10.5 | 10.5 - 10.55 |
| Close: | 10.83 - 10.93 | 10.93 - 11 |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Mon, 02 Jun 2025
Rapport's Epilepsy Drug RAP-219 Hits Full Enrollment in Phase 2a Trial, September Results Ahead - Stock Titan
Thu, 08 May 2025
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth - simplywall.st
Wed, 16 Apr 2025
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com
Mon, 31 Mar 2025
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Wed, 26 Mar 2025
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Sat, 15 Mar 2025
Several Insiders Invested In Rapport Therapeutics Flagging Positive News - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 105.2 (%) |
| Shares Short | 2,470 (K) |
| Shares Short P.Month | 2,440 (K) |
| EPS | -3.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -33.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -2.86 |
| PEG Ratio | 0 |
| Price to Book value | 1.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|